Anti-vascular endothelial growth factor therapy in breast cancer - Wikidata - awgldk - TriplyDB

Anti-vascular endothelial growth factor therapy in breast cancer

Anti-vascular endothelial growth factor therapy in breast cancer

http://www.wikidata.org/entity/Q26999473

about

Common Effects on Cancer Cells Exerted by a Random Positioning Machine and a 2D Clinostat.Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions.Identifications of novel mechanisms in breast cancer cells involving duct-like multicellular spheroid formation after exposure to the Random Positioning Machine Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Sorafenib for the treatment of breast cancer.Advancing Immunotherapy in Metastatic Breast Cancer.Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion

P2860

Q35746005-94258C29-EE84-4483-9745-6C834668CF73 Q36087693-E651ACAC-37BB-47E5-B359-914D1E38E25D Q36404008-F5B4B921-12C2-405D-9A9E-C493FAABA093 Q36941381-425955A8-4B56-4BA3-B6A2-5877892AD0DA Q37187766-18A02B48-5648-41FE-874D-3290B436A579 Q37269117-2AB5F094-866B-4D80-BD22-64C94323D1A5 Q37534859-A912D11F-7518-4720-B1BF-41E802860FF7 Q37729290-B04A41E6-91F4-49B7-806F-4A5075C70594 Q38498207-3FFBACAD-9218-432E-A63E-897505E527DB Q38690276-F0C65AED-66E2-4107-9DAB-A7D6B98AEA1F Q38852051-F6942B98-9073-4399-BD30-9AEF15D05E78 Q38881805-C5BD0E5F-4943-42D9-BF15-42D98434F590 Q39324161-D91858A3-7C96-4F81-9AC5-FB8A07F1C9B7 Q41573990-49639870-98C9-4EF0-B929-34100D43FBEC Q47275348-58CA12C5-B6FA-4344-9FDF-C77DB12D2A3E Q51213425-783D618A-31F8-40E5-9257-7BA47618A1FC Q59137325-5210E0A2-6BB7-430E-A1D7-46763A82B8C0

P2860

Anti-vascular endothelial growth factor therapy in breast cancer

http://www.wikidata.org/entity/Q26999473

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Anti-vascular endothelial growth factor therapy in breast cancer

@ast

Anti-vascular endothelial growth factor therapy in breast cancer

@en

Anti-vascular endothelial growth factor therapy in breast cancer

@nl

type

label

Anti-vascular endothelial growth factor therapy in breast cancer

@ast

Anti-vascular endothelial growth factor therapy in breast cancer

@en

Anti-vascular endothelial growth factor therapy in breast cancer

@nl

prefLabel

Anti-vascular endothelial growth factor therapy in breast cancer

@ast

Anti-vascular endothelial growth factor therapy in breast cancer

@en

Anti-vascular endothelial growth factor therapy in breast cancer

@nl

P1433

Q26999473-F9F319C9-ABAB-4BA0-8C82-F6FABE87701C

P1476

Q26999473-EABB3451-A2FF-48BF-975F-90DA550CEB32

P2093

Q26999473-0337D617-1512-4AA5-A8F4-8E3DE2BE3343

Q26999473-39AAC79C-0801-4272-9A31-659AB6AB8E6A

Q26999473-49C08F18-2BD0-466A-93BA-587C210A2142

Q26999473-646FCF23-77A5-4CD7-88D4-B920BB54FDAF

Q26999473-AC639B18-7AB9-4657-A80E-5C32FF176837

P275

Q26999473-CDF32C08-2417-4359-B7E8-9029EAAAD067

P2860

Q26999473-0007876E-A338-4658-8BB1-51064A2DABEB

Q26999473-06345484-2838-4296-95B6-3E1E5F8800F6

Q26999473-068CAFA1-A5C2-4871-9D91-9B77984A643B

Q26999473-06D6F4C2-1B55-4D02-9A5A-D1EC6C045761

Q26999473-0941047A-45E9-4CB2-B97E-C497E47BCA50

Q26999473-116BCA55-B132-4CB3-A862-A16F0022F5F8

Q26999473-15D45ADF-F7FF-41EA-9056-D32FB88F7506

Q26999473-172E2EB6-37B8-48C1-9C52-21BC9DCFCEBE

Q26999473-19579C0A-013F-4CE3-8415-BC7A52F0AE4E

Q26999473-1A757497-5DAE-46F9-87A1-1A5187340229

P304

Q26999473-CC068290-233F-4C95-924D-88A75A24C74D

P31

Q26999473-C69F4739-847A-4136-9797-C0B3100A0758

P3181

Q26999473-4B5A6E7A-6979-41D6-A7F1-A4EF448B7962

P356

Q26999473-2166E97C-7BA6-421A-A398-F3C50C950AA3

P407

Q26999473-C6B5BCC9-6606-4B27-9400-23D8372FB8F5

P433

Q26999473-0E8E4271-4D17-4B3D-932E-8F2D79AB57B0

P478

Q26999473-931252E2-D640-4774-A90A-615A33B1AA74

P50

Q26999473-53CDC4A6-0F06-44F4-A389-972ADEB5EF59

Q26999473-68592AC4-5D53-47FB-8F00-439944DB96CB

P5008

Q26999473-86956203-B227-452B-BF63-EFDB43FC7815

P577

Q26999473-0A71D9F1-8A05-4045-9F94-66938C69ED99

P5875

Q26999473-1B52DB58-8D7B-499D-8FE7-F1503A1F276B

P698

Q26999473-04EBAD1A-3367-4671-B58B-83A276630DBD

P921

Q26999473-675E689B-8762-486B-966A-637119078494

Q26999473-71D87E16-4831-42A7-9C27-9854B26511D3

Q26999473-72D7B715-7D21-41DB-A72A-FB6FB31382C9

Q26999473-B732FB8B-1D4D-42F2-BB70-C6834B0952C5

P932

Q26999473-F4063389-B58C-4E21-90CB-EC32BBEDE19D

P3181

P356

P1433

International Journal of Molecular Sciences

P1476

Anti-vascular endothelial growth factor therapy in breast cancer

@en

P2093

Britt Elmedal Laursen

http://www.w3.org/2001/XMLSchema#string

Daniela Grimm

http://www.w3.org/2001/XMLSchema#string

Elisabeth Warnke

http://www.w3.org/2001/XMLSchema#string

Malin L T Knutsson

http://www.w3.org/2001/XMLSchema#string

Tina Bøgelund Kristensen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Modes of resistance to anti-angiogenic therapy

Tumor angiogenesis: therapeutic implications

Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3

Molecular mechanisms and clinical applications of angiogenesis

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

P304

23024-23041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1218778

http://www.w3.org/2001/XMLSchema#string

P356

10.3390/IJMS151223024

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269773804

http://www.w3.org/2001/XMLSchema#string

P698

25514409

http://www.w3.org/2001/XMLSchema#string

P921

breast neoplasm

P932

4284752

http://www.w3.org/2001/XMLSchema#string